☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Travere Therapeutics
Travere Therapeutics’ Filspari (sparsentan) Receives the US FDA’s Full Approval for Treating IgA Nephropathy
September 6, 2024
PharmaShots Weekly Snapshots (March 11 – March 15, 2024)
March 15, 2024
Travere Therapeutics Reports sNDA Submission of Filspari (sparsentan) to the US FDA for Treating IgA Nephropathy (IgAN)
March 12, 2024
Travere Therapeutics Report Results for Filspari in 2 P-III Trial for the Treatment of IgA Nephropathy (IgAN) and Focal Segmental...
November 7, 2023
Travere Therapeutics’ Filspari (sparsentan) Receives the US FDA’s Approval for the Reduction of Proteinuria in IgA Nephropathy
February 21, 2023
Travere Therapeutics Reports US FDA Acceptance of NDA and Priority Review for Sparsentan to Treat IgA Nephropathy
May 17, 2022
Load more...
Back to Home